Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Dermata Therapeutics ( (DRMA) ).
On July 30, 2025, Dermata Therapeutics announced a one-for-10 reverse stock split, effective August 1, 2025, to consolidate its shares and adjust its trading on Nasdaq. This corporate action, approved by the Board on July 15, 2025, aims to enhance the company’s stock market positioning without altering stockholders’ equity percentages, except for fractional shares, which will be compensated in cash.
The most recent analyst rating on (DRMA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing innovative dermatology treatments.
Average Trading Volume: 124,145
Technical Sentiment Signal: Sell
Current Market Cap: $4.48M
Find detailed analytics on DRMA stock on TipRanks’ Stock Analysis page.